Dose-dependent cholesterol-lowering effects of D-003 on normocholesterolemic rabbits

Current Therapeutic Research - Clinical and Experimental

Volumn 61, Issue 7, 2000, Pages 460-468

  Gámez, Rafael ^a   Mendoza, Sarahí ^a   Más, Rosa ^a   Mesa, Rosario ^a   Castaño, Gladys ^b   Rodriguez, Beatriz ^b   Marrero, David ^a  

^a NATL CENTER FOR SCIENTIFIC RESEARCH   (Cuba)

^b Medical Surgical Research Center   (Cuba)

Author keywords

Cholesterol lowering drug; D 003; Lipid profile; Normocholesterolemic

Indexed keywords

D 003; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE CALCULATION; DOSE RESPONSE; FOOD INTAKE; HYPERCHOLESTEROLEMIA; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0033859508     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(00)80029-6     Document Type: Article

References (25)

1. 1. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease. JAMA. 1984; 251:351-364.
2. 2. Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. Reduction in the incidence of coronary heart disease. JAMA. 1984; 251:365-374.
3. 3. Frick MH, Elo O, Happa K, et al. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
4. 4. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383-1389.
5. 5. Sacks FM, Pfeffer MA, Moyé LA, et al, for the Cholesterol and Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med. 1996;335:1001-1009.
6. th Annual Scientific Session of the ACC; March 29-April 1, 1998; Atlanta, Ga.
7. 7. Shepherd S, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med. 1995;333:1301-1307.
8. 8. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (adult treatment panel II). JAMA. 1993;269:3015-3023.
9. 9. Pyorala K, De Backer G, Graham I, on behalf of the Task Force. Prevention of coronary heart disease in clinical practice. Recommendations of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Eur Heart J. 1994;15:1300-1331.
10. 10. Schectman G, Hiatt J. Drug therapy for hypercholesterolemia in patients with cardiovascular disease: Factors limiting achievement of lipid goals. Am J Med. 1996;100:197-204.
11. 11. Farmer JA, Otto AM Jr. Choosing the right lipid-regulating agent: A guide to selection. Drugs. 1996;52:649-661.
12. 12. Bhatnagar D. Lipid-lowering drugs in the management of hyperlipidaemia. Pharmacol Ther. 1998;79:205-230.
13. 13. Farnier M, Davignon J. Current and future treatment of hyperlipidemia: The role of statins. Am J Cardiol. 1998;82:3J-10J.
14. 14. González L, Marrero D, Laguna A, et al, inventors; Laboratorios Dalmer SA, assignee. Mixture of primary fatty acids of high molecular weight obtained from sugar cane wax and its pharmaceutical uses. Republic of South Africa Patent 98-2744. December 30, 1998.
15. 15. Laguna A, Magraner J, Más R, et al, inventors; Laboratories Dalmer SA, assignee. A mixture of higher primary aliphatic alcohols and its pharmaceutical uses. European Patent 0619802. November 4, 1998.
16. 16. Arruzazabala LM, Carbajal D, Más R, et al. Cholesterol-lowering effects of policosanol in rabbits. Biol Res. 1994;27:205-208.
17. 17. Rodríguez C, Mesa R, Más R, et al. Estudio del efecto sobre lípidos y lipoproteínas séricos y de la tolerancia al tratamiento oral con dosis crecientes de policosanol en monos (Macaca arctoides). Arch Venez Farmacol Ter. 1992;11:74-79.
18. 18. Pons P, Rodríguez M, Más R, et al. One-year efficacy and safety of policosanol in patients with type II hypercholesterolemia. Curr Ther Res. 1994;55:1084-1092.
19. 19. Aneiros E, Más R, Calderón B, et al. Effect of policosanol in lowering cholesterol levels in patients with type II hypercholesterolemia. Curr Ther Res. 1995;56:176-182.
20. 20. Castaño G, Más R, Nodarse M, et al. One-year study of the efficacy and safety of policosanol (5 mg twice daily) in the treatment of type II hypercholesterolemia. Curr Ther Res. 1995;56:296-304.
21. 21. Canetti M, Moreira M, Más R, et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II hyperlipoproteinaemia. Int J Clin Pharmacol Res. 1995;15:159-165.
22. 22. Zardoya R, Tula L, Castaño G, et al. Effects of policosanol on hypercholesterolemic patients with disturbances on serum biochemical indicators of hepatic function. Curr Ther Res. 1996;57:568-577.
23. 23. Más R, Castaño G, Illnait J, et al. Effect of policosanol in patients with type II hypercholesterolemia and additional coronary risk factors. Clin Pharmacol Ther. 1998;65:439-447.
24. 24. Seigler L, Wu WT. Separation of serum high-density lipoprotein for cholesterol determination: Ultracentrifugation vs precipitation with sodium phosphotungstat and magnesium chloride. Clin Chem. 1981;27:838-841.
25. 25. O'Brien PC, Shampo MC. Statistical considerations for performing multiple tests in a single experiment. 5. Comparing two therapies with respect to several end points. Mayo Clin Proc. 1998;63:1140-1143.